291 related articles for article (PubMed ID: 31921772)
1. Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs.
Naito M; Ohoka N; Shibata N; Tsukumo Y
Front Chem; 2019; 7():849. PubMed ID: 31921772
[TBL] [Abstract][Full Text] [Related]
2. Targeted protein degradation and drug discovery.
Naito M
J Biochem; 2022 Jul; 172(2):61-69. PubMed ID: 35468190
[TBL] [Abstract][Full Text] [Related]
3. Selective Degradation of Target Proteins by Chimeric Small-Molecular Drugs, PROTACs and SNIPERs.
Ishikawa M; Tomoshige S; Demizu Y; Naito M
Pharmaceuticals (Basel); 2020 Apr; 13(4):. PubMed ID: 32326273
[TBL] [Abstract][Full Text] [Related]
4.
Ohoka N; Okuhira K; Ito M; Nagai K; Shibata N; Hattori T; Ujikawa O; Shimokawa K; Sano O; Koyama R; Fujita H; Teratani M; Matsumoto H; Imaeda Y; Nara H; Cho N; Naito M
J Biol Chem; 2017 Mar; 292(11):4556-4570. PubMed ID: 28154167
[TBL] [Abstract][Full Text] [Related]
5. SNIPERs-Hijacking IAP activity to induce protein degradation.
Naito M; Ohoka N; Shibata N
Drug Discov Today Technol; 2019 Apr; 31():35-42. PubMed ID: 31200857
[TBL] [Abstract][Full Text] [Related]
6. Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER).
Ohoka N; Ujikawa O; Shimokawa K; Sameshima T; Shibata N; Hattori T; Nara H; Cho N; Naito M
Chem Pharm Bull (Tokyo); 2019 Mar; 67(3):203-209. PubMed ID: 30369550
[TBL] [Abstract][Full Text] [Related]
7. Protocols for Synthesis of SNIPERs and the Methods to Evaluate the Anticancer Effects.
Tsukumo Y; Tsuji G; Yokoo H; Shibata N; Ohoka N; Demizu Y; Naito M
Methods Mol Biol; 2021; 2365():331-347. PubMed ID: 34432253
[TBL] [Abstract][Full Text] [Related]
8. Specific non-genetic IAP-based protein erasers (SNIPERs) as a potential therapeutic strategy.
Ma Z; Ji Y; Yu Y; Liang D
Eur J Med Chem; 2021 Apr; 216():113247. PubMed ID: 33652355
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents.
Wang C; Zhang Y; Shi L; Yang S; Chang J; Zhong Y; Li Q; Xing D
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1437-1453. PubMed ID: 35589670
[TBL] [Abstract][Full Text] [Related]
10. Targeted Protein Degradation by Chimeric Compounds using Hydrophobic E3 Ligands and Adamantane Moiety.
Shoda T; Ohoka N; Tsuji G; Fujisato T; Inoue H; Demizu Y; Naito M; Kurihara M
Pharmaceuticals (Basel); 2020 Feb; 13(3):. PubMed ID: 32106507
[TBL] [Abstract][Full Text] [Related]
11. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
[TBL] [Abstract][Full Text] [Related]
12. [Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy].
Ohoka N
Yakugaku Zasshi; 2018; 138(9):1135-1143. PubMed ID: 30175757
[TBL] [Abstract][Full Text] [Related]
13. Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation.
Ohoka N; Morita Y; Nagai K; Shimokawa K; Ujikawa O; Fujimori I; Ito M; Hayase Y; Okuhira K; Shibata N; Hattori T; Sameshima T; Sano O; Koyama R; Imaeda Y; Nara H; Cho N; Naito M
J Biol Chem; 2018 May; 293(18):6776-6790. PubMed ID: 29545311
[TBL] [Abstract][Full Text] [Related]
14. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
Gu S; Cui D; Chen X; Xiong X; Zhao Y
Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
[TBL] [Abstract][Full Text] [Related]
15. Design and pharmaceutical applications of proteolysis-targeting chimeric molecules.
Liang Y; Nandakumar KS; Cheng K
Biochem Pharmacol; 2020 Dec; 182():114211. PubMed ID: 32866456
[TBL] [Abstract][Full Text] [Related]
16. Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins.
Ohoka N; Tsuji G; Shoda T; Fujisato T; Kurihara M; Demizu Y; Naito M
ACS Chem Biol; 2019 Dec; 14(12):2822-2832. PubMed ID: 31580635
[TBL] [Abstract][Full Text] [Related]
17. Bivalent Ligands for Protein Degradation in Drug Discovery.
Scheepstra M; Hekking KFW; van Hijfte L; Folmer RHA
Comput Struct Biotechnol J; 2019; 17():160-176. PubMed ID: 30788082
[TBL] [Abstract][Full Text] [Related]
18. Proteolysis targeting chimeras (PROTACs) in cancer therapy.
Ocaña A; Pandiella A
J Exp Clin Cancer Res; 2020 Sep; 39(1):189. PubMed ID: 32933565
[TBL] [Abstract][Full Text] [Related]
19. Monitoring and deciphering protein degradation pathways inside cells.
Daniels DL; Riching KM; Urh M
Drug Discov Today Technol; 2019 Apr; 31():61-68. PubMed ID: 31200861
[TBL] [Abstract][Full Text] [Related]
20. Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy.
Ohoka N; Shibata N; Hattori T; Naito M
Curr Cancer Drug Targets; 2016; 16(2):136-46. PubMed ID: 26560118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]